Relay Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

RLAY$19.94-2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Revenue:
License and other revenue	$—	$25,202	$10,007	$25,547
Total revenue	—	25,202	10,007	25,547
Operating expenses:
Research and development expenses	$76,619	$81,494	$251,014	$252,522
Change in fair value of contingent consideration liability	—	(1,200)	(13,206)	(4,355)
General and administrative expenses	19,750	18,485	59,688	58,184
Total operating expenses	96,369	98,779	297,496	306,351
Loss from operations	(96,369)	(73,577)	(287,489)	(280,804)
Other income:
Interest income	8,274	7,845	25,772	22,345
Other (expense) income	(10)	(2)	13	(19)
Total other income, net	8,264	7,843	25,785	22,326
Net loss	$(88,105)	$(65,734)	$(261,704)	$(258,478)
Net loss per share, basic and diluted	$(0.63)	$(0.54)	$(1.94)	$(2.12)
Weighted average shares of common stock, basic and diluted	140,229,056	122,231,255	134,651,728	121,843,116
Other comprehensive income (loss):
Unrealized holding gain	3,849	2,695	2,705	7,034
Total other comprehensive income	3,849	2,695	2,705	7,034
Total comprehensive loss	$(84,256)	$(63,039)	$(258,999)	$(251,444)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.